Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Decaens T, et al. Among authors: wermke m. Br J Cancer. 2021 Aug;125(3):465. doi: 10.1038/s41416-021-01403-z. Br J Cancer. 2021. PMID: 34079081 Free PMC article. No abstract available.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Decaens T, et al. Among authors: wermke m. Br J Cancer. 2021 Jul;125(2):190-199. doi: 10.1038/s41416-021-01334-9. Epub 2021 Apr 6. Br J Cancer. 2021. PMID: 33824476 Free PMC article. Clinical Trial.
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.
Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley JL. Le Tourneau C, et al. Among authors: wermke m. J Immunother Cancer. 2018 Oct 22;6(1):111. doi: 10.1186/s40425-018-0424-9. J Immunother Cancer. 2018. PMID: 30348224 Free PMC article. Clinical Trial.
Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation.
Schönefeldt C, Sockel K, Wehner R, Sopper S, Wolf D, Wermke M, Thiede C, Oelschlägel U, Ehninger G, Bornhäuser M, Platzbecker U, Schmitz M. Schönefeldt C, et al. Among authors: wermke m. Blood Cancer J. 2013 Aug 30;3(8):e136. doi: 10.1038/bcj.2013.35. Blood Cancer J. 2013. PMID: 23995045 Free PMC article. No abstract available.
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse.
Sockel K, Stölzel F, Hönl F, Baldauf H, Röllig C, Wermke M, von Bonin M, Teipel R, Link-Rachner C, Brandt K, Kroschinsky F, Hänel M, Morgner A, Klesse C, Ehninger G, Platzbecker U, Bornhäuser M, Schetelig J, Middeke JM. Sockel K, et al. Among authors: wermke m. Cancer Manag Res. 2022 Feb 15;14:547-559. doi: 10.2147/CMAR.S339846. eCollection 2022. Cancer Manag Res. 2022. PMID: 35210852 Free PMC article.
188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
Lauter A, Strumpf A, Platzbecker U, Schetelig J, Wermke M, Radke J, Kiani A, Wunderlich G, Thiede C, Ehninger G, Kotzerke J, Bornhäuser M. Lauter A, et al. Among authors: wermke m. Br J Haematol. 2010 Mar;148(6):910-7. doi: 10.1111/j.1365-2141.2009.08025.x. Epub 2009 Dec 7. Br J Haematol. 2010. PMID: 19995390 Free article. Clinical Trial.
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.
Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schönefeldt C, Mair S, Plodeck V, Laniado M, Weiss G, Schetelig J, Ehninger G, Theurl I, Bornhäuser M, Platzbecker U. Wermke M, et al. Clin Cancer Res. 2012 Dec 1;18(23):6460-8. doi: 10.1158/1078-0432.CCR-12-1683. Epub 2012 Sep 18. Clin Cancer Res. 2012. PMID: 22991415
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, Thieblemont C, Wermke M, Song KW, Avivi I, Kuruvilla J, Dührsen U, Zheng Y, Vardhanabhuti S, Dong J, Bot A, Rossi JM, Plaks V, Sherman M, Kim JJ, Kerber A, Kersten MJ. Topp MS, et al. Among authors: wermke m. Br J Haematol. 2021 Nov;195(3):388-398. doi: 10.1111/bjh.17673. Epub 2021 Sep 29. Br J Haematol. 2021. PMID: 34590303 Free PMC article. Clinical Trial.
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U. Platzbecker U, et al. Among authors: wermke m. BMC Cancer. 2022 May 21;22(1):569. doi: 10.1186/s12885-022-09622-0. BMC Cancer. 2022. PMID: 35597904 Free PMC article.
106 results